CHILDHOOD ARTHRITIS AND RHEUMATOLO… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2014

Legal Domicile

Principal Officer

ROBERT COLBERT MD PHD

Phone

2027721028

Tax Period

2023-01-01 to 2023-12-31

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE, founded in 2014, is a mid-sized nonprofit in the Diseases & Disorders sector that reported $10.8M in total revenue in fiscal year 2023.

Mission

CARRA MEMBERS WORK TOGETHER TO CAPITALIZE ON OPPORTUNITIES, ACTIVELY DEVELOP A STRUCTURE AND A SCIENTIFIC AGENDA, AND COLLABORATE WITH POTENTIAL FUNDING SOURCES TO CREATE A RESEARCH ALLIANCE THAT BENEFITS OUR PATIENTS. CARRA CONDUCTS COLLABORATIVE RESEARCH TO PREVENT, TREAT AND CURE PEDIATRIC RHEUMATIC DISEASES.

Program Service Accomplishments

Program 1

Expenses: $6,772,261 Revenue: $5,731,677

CARRA REGISTRY: CARRA AND THE DUKE CLINICAL RESEARCH INSTITUTE (DCRI) ARE COLLABORATING TO LAUNCH THE SECOND PHASE OF THE CARRA REGISTRY, A REGISTRY OF CHILDREN AND YOUNG ADULTS WITH PEDIATRIC-ONSET RHEUMATIC CONDITIONS SUCH AS JUVENILE IDIOPATHIC ARTHRITIS (JIA). THE REGISTRY IS A CORNERSTONE OF CARRA AND PROVIDES DISEASE AND TREATMENT DATA ON CHILDREN WITH A VARIETY OF RHEUMATIC DISEASES.

Program 2

Expenses: $528,432 Revenue: $351,500

ANNUAL MEETING: PROVIDES MANY OPPORTUNITIES TO DEVELOP AND REFINE SCIENTIFIC APPROACHES TO QUESTIONS IN CLINICAL AND TRANSLATIONAL RESEARCH, WHILE NETWORKING WITH COLLEAGUES. THE MEETING OFFERS A...

ANNUAL MEETING: PROVIDES MANY OPPORTUNITIES TO DEVELOP AND REFINE SCIENTIFIC APPROACHES TO QUESTIONS IN CLINICAL AND TRANSLATIONAL RESEARCH, WHILE NETWORKING WITH COLLEAGUES. THE MEETING OFFERS A UNIQUE, INTERACTIVE FORMAT WITH SESSIONS THAT ENCOURAGE ACTIVE PARTICIPATION, INCLUDING BRAINSTORMING AND CONTRIBUTING TO NEW RESEARCH INITIATIVES AND IDEAS.

Program 3

Expenses: $1,371,719 Revenue: $1,198,421

GRANT SUPPORT TO OTHERS: CARRA OFFERS MEMBERS VARIOUS FUNDING AND INTERNSHIP OPPORTUNITIES TO FURTHER RESEARCH THAT LEVERAGES THE CARRA NETWORK AND POSITIVELY IMPACTS THE PEDIATRIC RHEUMATOLOGY...

GRANT SUPPORT TO OTHERS: CARRA OFFERS MEMBERS VARIOUS FUNDING AND INTERNSHIP OPPORTUNITIES TO FURTHER RESEARCH THAT LEVERAGES THE CARRA NETWORK AND POSITIVELY IMPACTS THE PEDIATRIC RHEUMATOLOGY SCIENTIFIC COMMUNITY AND ADVANCES THE CARRA MISSION.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $525,959

Program Service Revenue $9,748,979

Investment Income $565,525

Other Revenue $541

TOTAL REVENUE $10,841,004

Expense Breakdown

Grants Paid $1,281,542

Salaries & Benefits $1,832,151

Fundraising Expenses $190,141

Program Expenses $10,030,709

Other Expenses $8,420,658

TOTAL EXPENSES $11,534,351

Year-over-Year Comparison

	2023	2022	Change
Revenue	$10,841,004	$10,561,848	+0.0%
Expenses	$11,534,351	$11,144,720	+0.0%
Net Income	$-693,347	$-582,872	+0.2%

Key Indicators

✓ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$240,772

Total Directors

$240,772

Key Employees

$363,184

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MATHIEU NELESSEN	CEO	40.00	Key Emp	$308,104	$55,080	$363,184
ROBERT COLBERT MD PHD	PRESIDENT	15.00	Officer Director	$40,000	$0	$40,000
EMILY VON SCHEVEN MD MAS	PAST PRESIDENT	10.00	Officer Director	$67,446	$0	$67,446
STACY ARDOIN MD	VICE PRESIDENT	10.00	Officer Director	$69,120	$0	$69,120
CHRISTY SANDBORG MD	CHAIR-SECRETARY	3.00	Officer Director	$0	$0	$0
JAY MEHTA MD MS	TREASURER	10.00	Officer Director	$64,206	$0	$64,206
CAROL WALLACE MD	DIRECTOR	1.00	Director	$0	$0	$0
HARRY SAAL PHD	DIRECTOR	1.00	Director	$0	$0	$0
LEIGH WHITE JD	DIRECTOR	1.00	Director	$0	$0	$0
DANIEL SOLOMON MD PHD	DIRECTOR	1.00	Director	$0	$0	$0
JOHN SUNDY MD PHD	DIRECTOR	1.00	Director	$0	$0	$0
ROBERT FUHLBRIGGE MD PHD	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$10,841,004	$11,534,351	$17,407,019	$-693,347
2022	$10,561,848	$11,144,720	$17,073,918	$-582,872
2021	$6,468,070	$10,024,485	$18,755,308	$-3,556,415
2020	$5,833,140	$8,088,772	$18,697,197	$-2,255,632
2019	$11,029,270	$8,415,703	$20,873,541	$2,613,567
2018	$9,976,474	$7,876,769	$18,423,173	$2,099,705

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE